July 24 (Reuters) - Theratechnologies Inc TH.TO :
* Theratechnologies Inc - announces new findings with investigational Antiretroviral Ibalizumab and with EGRIFTA
* Phase IIb trial, TMB-202 data for ibalizumab show no significant difference in susceptibility in patient HIV isolates